Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer
Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer
复制标题
DOI：
10.1200/jco.2009.24.2446
复制
发表时间：
2009-11-20
影响因子：
45.3
通讯作者：
Neoptolemos, John P.
中科院分区：
文献类型：
--
作者：
Cunningham, David;Chau, Ian;Neoptolemos, John P.
目的吉西他滨和氟嘧啶是治疗晚期胰腺癌的有效药物。这项开放标签研究旨在比较随机分配给GEM单独或GEM加卡培他滨（GEM- cap）患者的总生存期（OS）。患者和方法先前未经治疗的组织学或细胞学证实的局部晚期或转移性胰腺癌，其表现状态良好
PurposeBoth gemcitabine (GEM) and fluoropyrimidines are valuable treatment for advanced pancreatic cancer. This open-label study was designed to compare the overall survival (OS) of patients randomly assigned to GEM alone or GEM plus capecitabine (GEM-CAP).Patients and MethodsPatients with previously untreated histologically or cytologically proven locally advanced or metastatic carcinoma of the pancreas with a performance status